Retevmo (selpercatinib)

pCPA File Number: 21856

Negotiation Status:

Concluded with an LOI

Indication(s):

indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients

Sponsor/Manufacturer:

Eli Lilly Canada Inc.

CADTH Project Number:

PC0261

pCPA Engagement Letter Issued:

2022-11-17

Negotiation Process Concluded:

2023-03-31